113 例结核病患者氟喹诺酮类抗菌药物的不良反应报告分析

doi:10.19803/j.1672-8629.2022.04.13

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (4): 404-407.
DOI: 10.19803/j.1672-8629.2022.04.13

113 例结核病患者氟喹诺酮类抗菌药物的不良反应报告分析

朱娜¹, 阚晓宏², 吴欣俐¹, 丁海华¹, 薛淑雅¹, 张云玲^1,*

¹安徽省胸科医院药剂科,安徽合肥 230022;
²安徽省胸科医院科教科,安徽合肥 230022

收稿日期:2021-02-18 出版日期:2022-04-15 发布日期:2022-04-15
通讯作者: ^*张云玲,女,硕士,副主任药师,临床药学。E-mail：yl1525@126.com
作者简介:朱娜,女,硕士,主管药师,临床药学。
基金资助:
重大新药创制国家科技重大专项2018年度（2018ZX10722302- 001-006）

113 reports of adverse drug reactions induced by fluoroquinolones in patients with tuberculosis

ZHU Na¹, KAN Xiaohong², WU Xinli¹, DING Haihua¹, XUE Shuya¹, ZHANG Yunling^1,*

¹Department of Pharmacy, Anhui Chest Hospital, Hefei Anhui 230022, China;
²Department of Science and Education, Anhui Chest Hospital, Hefei Anhui 230022, China

Received:2021-02-18 Online:2022-04-15 Published:2022-04-15

摘要/Abstract

摘要： 目的对结核病患者氟喹诺酮类药物的药品不良反应（adverse drug reaction, ADR）报告进行分析,为临床合理应用提供参考。方法采用回顾性研究方法,对2013年1月1日至2020年6月30日期间我院结核病患者使用氟喹诺酮类药物发生ADR的病例进行调查并统计分析。结果共收到113例结核病患者氟喹诺酮类药物ADR报告,其中严重ADR占10.62%。涉及3种氟喹诺酮类药物,依次为左氧氟沙星、依诺沙星、莫西沙星。累及系统-器官主要为皮肤及附件损害、全身反应和胃肠系统等。静脉给药方式所致ADR多于口服。7.08%的患者存在不合理用药问题,表现为遴选药物不适宜。结论临床治疗过程中应该高度重视结核病患者氟喹诺酮类药物ADR的监测,发现ADR及时采取有效措施,提高用药的安全性。

关键词: 氟喹诺酮, 左氧氟沙星, 依诺沙星, 莫西沙星, 药品不良反应, 药物警戒

Abstract: Objective To analyse the adverse drug reactions (ADR) reports induced by fluoroquinolones in patients with tuberculosis, so as to provide reference for rational drug use. Methods The cases of ADR induced by fluoroquinolones in patients with tuberculosis from January 1, 2013 to June 30, 2020 in our hospital were retrospectively investigated and analyzed. Results A total of 113 cases of ADR of fluoroquinolones were reported in tuberculosis patients, of which serious ADR accounted for 10.62%. Three kinds of fluoroquinolones were involved, levofloxacin, enoxacin, and moxifloxacin in turn. Clinical manifestations involved skin and appendages disorders, systemic reaction, gastrointestinal system. ADR induced by intravenous administration was more than oral administration. 7.08 % of the patients had irrational drug use, which manifested as unsuitable selection of drugs. Conclusion The monitoring of ADR of fluoroquinolones in tuberculosis patients should be attached great importance in clinical treatment, and effective measures should be taken timely to improve the safety of drug use.

Key words: fluoroquinolones, levofloxacin, enoxacin, moxifloxacin, adverse drug reaction, pharmacovigilance

中图分类号:

R974

朱娜, 阚晓宏, 吴欣俐, 丁海华, 薛淑雅, 张云玲. 113 例结核病患者氟喹诺酮类抗菌药物的不良反应报告分析[J]. 中国药物警戒, 2022, 19(4): 404-407.

ZHU Na, KAN Xiaohong, WU Xinli, DING Haihua, XUE Shuya, ZHANG Yunling. 113 reports of adverse drug reactions induced by fluoroquinolones in patients with tuberculosis[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 404-407.

参考文献

[1] World Health Organization.Global tuberculosis report 2020[EB/OL].(2020-10-27)[2021-03-20].https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2020.
[2] Chinese Medical Association.Guidelines for clinical treatment: tuberculosis volume(临床诊疗指南:结核病分册)[M]. Beijing: People's Medical Publishing House, 2005: 65, 80.
[3] TAN SY, LI YQ.Application of fluoroquinolones in the treatment of multidrug-resistant tuberculosis[J]. Chinese Journal of Antituberculosis(中国防痨杂志), 2005,27(4): 267-270.
[4] Chinese Antituberculosis Association. Chinese Antituberculosis Association(2019)[J]. Chinese Journal of Antituberculosis(中国防痨杂志), 2019, 41(10): 1025-1073.
[5] DOOSOO J.WHO treatment guidelines for drug-resistant tuberculosis,2016 update: applicability in South Korea[J]. Tuberculosis & Respiratory Diseases, 2017, 80(4): 336-343.
[6] SONG WJ.Clinical analysis of adverse reactions of fluoroquinolones[J]. Chinese Journal of Modern Drug Application(中国现代药物应用),2015, 9(15): 158-159.
[7] FAN M.Literature analysis on ADR induced by quinolones in the elderly[J].China Pharmacy(中国药房), 2010, 21(18): 1704-1706.
[8] Jiao WW, Sun L, Xiao J, et al.Guidelines for national tuberculosis programmes-management of tuberculosis in children(version 2)[J]. Chinese Journal of Evidence Based Pediatrics(中国循证儿科杂志),2016, 11(1): 65-74.
[9] YANG XJ, XIE HT, WANG HF.Analysis of 176 new and severe ADR reports[J]. China Pharmacy(中国药房), 2014, 25(14): 1301-1303.
[10] TAN LL.Clinical adverse reactions of quinolone antibacterial drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2013, 10(2): 92-95.
[11] National Medical Products Administration. Adverse drug reactions information bulletin (Issue 58) focuses on serious adverse reactions to fluoroquinolones [EB/OL]. (2013-11-21)[2021-03-14]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/yjjsh/ypblfytb/20131121120001488.html.
[12] National Medical Products Administration. Notice of the General Administration of the People's Republic of China on the Revision of the instructions for fluoroquinolones for whole body use (No. 79, 2017)[EB/OL]. (2017-07-05)[2021-03-14].https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/ypshmshxdgg/20170705171401817.html.
[13] CHANG XY, GUO GM.Analysis of literature on adverse reactions to thrombocytopenia induced by quinolones[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(4): 227-230.
[14] LINDEN PDVD, STURKENBOOM MCJM, HERINGS RMC.et al.Fluoroquinolones and risk of Achilles tendon disorders: case-control study[J]. British Medical Journal, 2002, 324(7349): 1306-1307.
[15] SHU CHEN K, YUNG TAI C, YI TZU L, et al.Association between recent use of fluoroquinolones and rhegmatogenous retinal detachment: a population-based cohort study[J]. Clinical Infectious Diseases, 2014, 58(2): 197-203.
[16] MEHRZAD R, BARZA M.Weighing the adverse cardiac effects of fluoroquinolones: a risk perspective[J]. Journal of Clinical Pharmacology, 2015, 55(11): 1198-206.
[17] LIN X, LI J, REN HL.Analysis of 481 reports of adverse drug reactions induced by quinolone drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(10): 617-624.

113 例结核病患者氟喹诺酮类抗菌药物的不良反应报告分析

113 reports of adverse drug reactions induced by fluoroquinolones in patients with tuberculosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[11]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[12]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[13]	夏旭东, 黎美霞, 孙阳, 杨胜亚. 药品上市许可持有人药物警戒远程检查流程探讨[J]. 中国药物警戒, 2023, 20(9): 967-970.
[14]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[15]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.